Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
ApexOnco Front Page
Recent articles
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Boehringer discontinues brigimadlin while others continue to struggle.
The group could soon provide clarity on CTX112’s regulatory path.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The THIO-104 study listing is live, along with questions about funding the trial.
